Characterization of bipolar disorder patient-specific induced pluripotent stem cells from a family reveals neurodevelopmental and mRNA expression abnormalities.
- Authors
- Madison, J M; Zhou, F; Nigam, A; Hussain, A; Barker, D D; Nehme, R; van der Ven, K; Hsu, J; Wolf, P; Fleishman, M; O'Dushlaine, C; Rose, S; Chambert, K; Lau, F H; Ahfeldt, T; Rueckert, E H; Sheridan, S D; Fass, D M; Nemesh, J; Mullen, T E; Daheron, L; McCarroll, S; Sklar, P; Perlis, R H; Haggarty, S J
- Year
- 2015
- Journal
- Molecular psychiatry
- PMID
- 25733313
- DOI
- 10.1038/mp.2015.7
- PMCID
- PMC4440839
Bipolar disorder (BD) is a common neuropsychiatric disorder characterized by chronic recurrent episodes of depression and mania. Despite evidence for high heritability of BD, little is known about its underlying pathophysiology. To develop new tools for investigating the molecular and cellular basis of BD, we applied a family-based paradigm to derive and characterize a set of 12 induced pluripotent stem cell (iPSC) lines from a quartet consisting of two BD-affected brothers and their two unaffected parents. Initially, no significant phenotypic differences were observed between iPSCs derived from the different family members. However, upon directed neural differentiation, we observed that CXCR4 (CXC chemokine receptor-4) expressing central nervous system (CNS) neural progenitor cells (NPCs) from both BD patients compared with their unaffected parents exhibited multiple phenotypic differences at the level of neurogenesis and expression of genes critical for neuroplasticity, including WNT pathway components and ion channel subunits. Treatment of the CXCR4(+) NPCs with a pharmacological inhibitor of glycogen synthase kinase 3, a known regulator of WNT signaling, was found to rescue a progenitor proliferation deficit in the BD patient NPCs. Taken together, these studies provide new cellular tools for dissecting the pathophysiology of BD and evidence for dysregulation of key pathways involved in neurodevelopment and neuroplasticity. Future generation of additional iPSCs following a family-based paradigm for modeling complex neuropsychiatric disorders in conjunction with in-depth phenotyping holds promise for providing insights into the pathophysiological substrates of BD and is likely to inform the development of targeted therapeutics for its treatment and ideally prevention.
Genomic characterization of Family-811 quartet(A) The pedigree for Family-811 is shown. Males are squares and females are circles. Affected individuals are shaded while unaffected individuals are open. Individuals from the Family-811 quartet studied herein are shown with vermillion squares and circles. The associated Coriell identification numbers are shown below the individuals. GM05224 and GM05225 were both diagnosed with BD type I. (B) The familial relationship of these individuals was confirmed using identity-by-descent (IBD) analysis. The IBD1 and IBD2 components were plotted for the parent-parent, parent-offspring and offspring-offspring comparisons. Each of these comparisons agreed with the theoretic prediction of allele sharing for the given familial relationship [(IBD0, IBD1): parent-parent = (1,0), siblings = (1/4,1/2), parent-sibling = (0,1)].34 (C) The multidimensional scaling analysis confirmed that the Family-811 quartet was ethnically related to the CEU Hap Map population and the STEP-BP cohort of individuals used to identify genetically associated bipolar disorder loci. Plotted for comparison are HapMap individuals from Northern and Western Europe (CEU), Yoruba (YRB), and Han Chinese (HCB). (D) The complement of CNVs identified in the Family-811 quartet and their segregation, the size, and encompassed genes. Dark grey squares with 2βs indicate a homozygous locus while light grey squares indicate a hemizygous deletion locus, and white squares with a 3 indicate a copy number of 3. The pedigree at the top indicates the familial relationship. (E) The orange bars indicate the CNVs as determined by SNP analysis, purple bars indicate CNVs identified by droplet digital PCR and the green bars are genes identified as RefSeq genes.
Stepwise neural differentiation of Family-811 quartet iPSCs(A) Schematic of the two-dimensional iPSC neural induction protocol used. Each of the iPSC lines generated from the Family-811 quartet was capable of generating neural rosettes with a characteristic morphology that were manually dissected, passaged and expanded in culture. Each of the iPSC lines was capable of generating SOX1+ cells that could be expanded in vitro. (B) To derive comparable populations of NPCs, a cell surface signature described by Yuan et al.36 was used with FACS to isolate CD184+/CD271β/CD24+/CD15+ cells. A representative gating scheme and plot of the events for an experiment is shown. Representative images of CD184+/CD271β/CD24+/CD15+ cells from GM08330, GM08329, GM05225 and GM05224 stained for NESTIN (red) and DAPI (blue) for DNA. (C) FACS-purified NPCs from the iPSC lines indicated were differentiated into neurons for six weeks yielding post-mitotic neurons staining for the neuronal markers TuJ1 and MAP2. (D) A cell lineage diagram summarizes the cells and cell lines generated from fibroblasts and iPSCs from of each of the individuals in the Family-811 quartet. Xβs indicate NPC lines that were able to be initally isolated but were unable to be continually expand beyond four or five passages in vitro despite mutliple attempts. The scale bar is 100 Β΅m.
Phenotypic differences of NPCs derived from both BD-patient iPSCs compared to their unaffected parents(A) BrdU incorporation and staining was used to quantify proliferation of the two BD-patient (GM05225, GM05224) and their unaffected parental (GM08330, GM08329) NPC counterparts. (B) Bar graph summarizing the percent of cells of the total NESTIN+ cells that incorporated BrdU. The BD-patient NPCs exhibited a significant decrease in BrdU incorporation compared to the mean of the unaffected parents (*** indicates significant, t-test, p=0.001). (C) Upon differentiation, BD-patient NPCs (GM05224-3 NPC and GM05225-5 NPC) were found to extend neuritic processes, similar to the unaffected counterparts, but exhibited reduced viability after two weeks of differentiation. In the case of GM05225-5 almost no neurons remained in culture after six weeks. (D) Higher magnification of post-mitotic neurons from the parental control NPC line 8329-1 shown in (c). The scale bar is 100 Β΅m. Error bars depict standard deviation of the measurement.
Differential gene expression signature of BD-patient derived NPCs and neurons(A) Principle components analysis (PCA) of a custom PsychGene NanoString profiles from the Family-811 quartet using all 352 of the genes reveals similar grouping of cells by cell type. (B) Fibroblasts, iPSCs and NPCs were compared using probes against OCT4, NANOG, SOX2, ZFP42, DNMT3B, hTERT, MYC, GFP with total RNA from the human ES cell line H9 shown for comparison. (C) Volcano plots of [βLog10 (p-value) versus the Log2 (fold change expression)] of all genes (grey dots). Significant, differentially expressed genes (> 1.5-fold comparing BD cells to unaffected cells, moderated t-test p-value < 0.05, Benjamini-Hochberg corrected) were plotted with orange dots with a subset annotated by gene name. Those genes that were also significant when members of the Family-811 quartet were compared based on sex (i.e. GM08329 versus GM8330, GM05225 and GM05225) were colored green. Gene expression differences were found to be enriched in the BD-patient NPCs and neuronal populations. Each dot represents a gene expression assay (n=3) for the cell type indicated. Error bars depict standard deviation of the measurement.
Gene expression differences in the BD-patient iPSC neural derivativesDifferential gene expression (>1.5 fold at a significance of p<0.05 calculated using a moderated t-test and corrected using the Benjamini-Hochberg test) in (A) BD-patient CXCR4+ NPCs and (B) in BD-patient neurons relative to the unaffected parental cells. Genes with increased expression are shown in red; genes with deceased expression are shown in blue. (C) Agglomerative hierarchical clustering of the 53 differentially expressed genes between BD-patient CXCR4+ NPCs and differentiated neurons using a weighted pair-group average method and a Pearson correlation coefficient as the similarity metric. (D) DAPPLE protein-protein interaction network amongst differentially expressed genes form the PsychGene NanoString profiles between BD-patient CXCR4+ NPCs and differentiated neurons demonstrating a statistically significant high degree of interconnectivity for specific nodes (marked with *) and globally. (E) WNT module within the DAPPLE protein-protein interaction network amongst differentially expressed genes from the global RNA-seq analysis composed of WNT7B and four additional input seeds amongst the direct interactions all of which were downregulated (levels indicated with arrow) in the BD-patient CXCR4+ NPCs compared to the parental control CXCR4+ NPCs.(F) Rescue of DNA synthesis deficits in the BD-patient NPCs with WNT pathway activation. BrdU incorporation data with pairs of DMSO and CHIR-99021 treated cell lines represented with a symbol connected by a bar. Cell were treated for 16 hours with either DMSO (vehicle) or CHIR-99021 (5 Β΅M), labeled with BrdU, fixed, and stained to detect BrdU and NESTIN. Proliferation was measured by counting BrdU labeled nuclei and quantifying percent of NESTIN+ cells labeled with BrdU. The orange symbol and bars represent averages of the BrdU incorporation experiments in the presence of either DMSO or CHIR-99021. The proliferation defect observed in the BD-patient CXCR4+ NPCs was significantly (pair-wise t-test, p=0.02) decreased with CHIR-99021 treatment while the proliferation of the unaffected parental CXCR4+ NPCs was not changed. (G) CHIR-99021 treatment (16 hours, 5 Β΅M) alters the expression of a subset of WNT pathway responsive genes in the BD-patient CXCR4+ NPCs measured using the PsychGene NanoString probe set. Several genes were upregulated (> 1.5-fold; p-value <0.05 Benjamini-Hochberg corrected) in the BD-patient NPC cell line, including CD44, LEF1, AXIN2 and down regulated (GBX2), while others were only responsive in the parental control lines (ATOH, GSK3B) unaffected. Error bars depict standard deviation of the measurement.
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| DNA methylation patterns and epigenetic aging associated with suicide attempts in bipolar disorder. | Mitjans M et al. | β | 2026 | β |
| Generation of two induced pluripotent stem cell (iPSC) lines (HZSMHCI001-A and HZSMHCI004-A) from a mother-child dyad with major depressive disorder and bipolar disorder. | Zhao J et al. | β | 2026 | β |
| Cerebral organoid research for pediatric patients with neurological disorders. | Eun J et al. | β | 2025 | β |
| Differential effects of lithium on metabolic dysfunctions in astrocytes derived from bipolar disorder patients. | Baek GH et al. | β | 2025 | β |
| Advances in the understanding of the pathophysiology of schizophrenia and bipolar disorder through induced pluripotent stem cell models. | Perrottelli A et al. | β | 2024 | β |
| A Systematic Review of the Molecular and Cellular Alterations Induced by Cannabis That May Serve as Risk Factors for Bipolar Disorder. | Delgado-Sequera A et al. | β | 2024 | β |
| Comparing stem cells, transdifferentiation and brain organoids as tools for psychiatric research. | Bellon A | β | 2024 | β |
| Correspondence to "Bipolar disorder-iPSC derived neural progenitor cells exhibit dysregulation of store-operated Ca<sup>2+</sup> entry and accelerated differentiation" by Hewitt et al. (PMID: 37402854). | Yde Ohki CM et al. | β | 2024 | β |
| Exploring mood disorders and treatment options using human stem cells. | Hudock A et al. | β | 2024 | β |
| Impaired neural stress resistance and loss of REST in bipolar disorder. | Meyer K et al. | β | 2024 | β |
| Stem cell therapy for the treatment of psychiatric disorders: a real hope for the next decades. | Villanueva R | β | 2024 | β |
| A characteristic cerebellar biosignature for bipolar disorder, identified with fully automatic machine learning. | Thomaidis GV et al. | β | 2023 | β |
| Advances and Applications of Brain Organoids. | Li Y et al. | β | 2023 | β |
| Advances in the knowledge and therapeutics of schizophrenia, major depression disorder, and bipolar disorder from human brain organoid research. | Villanueva R | β | 2023 | β |
| Bipolar disorder-iPSC derived neural progenitor cells exhibit dysregulation of store-operated Ca<sup>2+</sup> entry and accelerated differentiation. | Hewitt T et al. | β | 2023 | β |
| Huntingtin turnover: modulation of huntingtin degradation by cAMP-dependent protein kinase A (PKA) phosphorylation of C-HEAT domain Ser2550. | Lee Y et al. | β | 2023 | β |
| Identification of a psychiatric risk gene NISCH at 3p21.1 GWAS locus mediating dendritic spine morphogenesis and cognitive function. | Yang ZH et al. | β | 2023 | β |
| Neurite outgrowth deficits caused by rare PLXNB1 mutation in pediatric bipolar disorder. | Yang G et al. | β | 2023 | β |
| RNA Biomarkers in Bipolar Disorder and Response to Mood Stabilizers. | Pisanu C et al. | β | 2023 | β |
| Abnormalities in the migration of neural precursor cells in familial bipolar disorder. | Sukumaran SK et al. | β | 2022 | β |
| Brain injury and inflammation genes common to a number of neurological diseases and the genes involved in the genesis of GABAnergic neurons are altered in monoamine oxidase B knockout mice. | Chen K et al. | β | 2022 | β |
| Differentiation of Human Induced Pluripotent Stem Cells into Cortical Neurons to Advance Precision Medicine. | Silva MC et al. | β | 2022 | β |
| Human-Induced Pluripotent Stem Cell Technology: Toward the Future of Personalized Psychiatry. | Alciati A et al. | β | 2022 | β |
| Inhibition of glycogen synthase kinase 3 by lithium, a mechanism in search of specificity. | Chatterjee D et al. | β | 2022 | β |
| The differences in serum C1q levels between first-episode patients with bipolar disorder and major depressive disorder. | Chen Q et al. | β | 2022 | β |
| The genetics of bipolar disorder with obesity and type 2 diabetes. | Miola A et al. | β | 2022 | β |
| Abnormalities in migration of neural precursor cells in familial bipolar disorder | Sukumaran SK et al. | β | 2021 | β |
| Advances toward precision medicine for bipolar disorder: mechanisms & molecules. | Haggarty SJ et al. | β | 2021 | β |
| Induced Pluripotent Stem Cells in Psychiatry: An Overview and Critical Perspective. | De Los Angeles A et al. | β | 2021 | β |
| Mood Stabilizers in Psychiatric Disorders and Mechanisms Learnt from In Vitro Model Systems. | Nayak R et al. | β | 2021 | β |
| N-3 polyunsaturated fatty acids promote astrocyte differentiation and neurotrophin production independent of cAMP in patient-derived neural stem cells. | Yu JZ et al. | β | 2021 | β |
| TCF7L2 lncRNA: a link between bipolar disorder and body mass index through glucocorticoid signaling. | Liu D et al. | β | 2021 | β |
| Translational genomics and beyond in bipolar disorder. | Zhang C et al. | β | 2021 | β |
| Valproate reverses mania-like behaviors in mice via preferential targeting of HDAC2. | Logan RW et al. | β | 2021 | β |
| 16p11.2 microdeletion imparts transcriptional alterations in human iPSC-derived models of early neural development. | Roth JG et al. | β | 2020 | β |
| 5-aminoisoquinolinone attenuates social behavior deficits and immune abnormalities in the BTBR T<sup>+</sup> Itpr3<sup>tf</sup>/J mouse model for autism. | Ahmad SF et al. | β | 2020 | β |
| Brain Organoids: A Promising Living Biobank Resource for Neuroscience Research. | Li S et al. | β | 2020 | β |
| Developmental excitation-inhibition imbalance underlying psychoses revealed by single-cell analyses of discordant twins-derived cerebral organoids. | Sawada T et al. | β | 2020 | β |
| Discovery of suppressors of CRMP2 phosphorylation reveals compounds that mimic the behavioral effects of lithium on amphetamine-induced hyperlocomotion. | Zhao WN et al. | β | 2020 | β |
| Effect of Cell Spreading on Rosette Formation by Human Pluripotent Stem Cell-Derived Neural Progenitor Cells. | Townshend RF et al. | β | 2020 | β |
| Gene expression in peripheral blood in treatment-free major depression. | Cuellar-Barboza AB et al. | β | 2020 | β |
| Human induced pluripotent stem cells technology in treatment resistant depression: novel strategies and opportunities to unravel ketamine's fast-acting antidepressant mechanisms. | Marcatili M et al. | β | 2020 | β |
| Human pluripotent stem cell-derived models and drug screening in CNS precision medicine. | Silva MC et al. | β | 2020 | β |
| Identification of Molecular Signatures in Neural Differentiation and Neurological Diseases Using Digital Color-Coded Molecular Barcoding. | Salerno D et al. | β | 2020 | β |
| Integrative analyses prioritize GNL3 as a risk gene for bipolar disorder. | Meng Q et al. | β | 2020 | β |
| Label-free proteomics differences in the dorsolateral prefrontal cortex between bipolar disorder patients with and without psychosis. | Ho AM et al. | β | 2020 | β |
| Mechanisms Underlying the Hyperexcitability of CA3 and Dentate Gyrus Hippocampal Neurons Derived From Patients With Bipolar Disorder. | Stern S et al. | β | 2020 | β |
| Mental health dished up-the use of iPSC models in neuropsychiatric research. | McNeill RV et al. | β | 2020 | β |
| Modeling Brain Disorders Using Induced Pluripotent Stem Cells. | Vadodaria KC et al. | β | 2020 | β |
| Modeling neuropsychiatric disorders using human induced pluripotent stem cells. | Wang M et al. | β | 2020 | β |
| Modeling Psychiatric Disorder Biology with Stem Cells. | Das D et al. | β | 2020 | β |
| Neurodevelopmental pathways in bipolar disorder. | Kloiber S et al. | β | 2020 | β |
| Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection. | CuΓ©llar-Barboza AB et al. | β | 2020 | β |
| The application of human pluripotent stem cells to model the neuronal and glial components of neurodevelopmental disorders. | Lee KM et al. | β | 2020 | β |
| Unprecedented Potential for Neural Drug Discovery Based on Self-Organizing hiPSC Platforms. | Cota-Coronado A et al. | β | 2020 | β |
| Variation of Human Neural Stem Cells Generating Organizer States InΒ Vitro before Committing to Cortical Excitatory or Inhibitory Neuronal Fates. | Micali N et al. | β | 2020 | β |
| Whole blood transcriptome analysis in bipolar disorder reveals strong lithium effect. | Krebs CE et al. | β | 2020 | β |
| Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons. | Vadodaria KC et al. | β | 2019 | β |
| Clinical phenotype and genetic risk factors for bipolar disorder with binge eating: an update. | Cuellar-Barboza AB et al. | β | 2019 | β |
| Drug discovery in psychopharmacology: from 2D models to cerebral organoidsβ©. | Rossetti AC et al. | β | 2019 | β |
| Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development. | Kaffman A et al. | β | 2019 | β |
| Genetic Associations between Voltage-Gated Calcium Channels and Psychiatric Disorders. | Andrade A et al. | β | 2019 | β |
| <i>In Vitro</i> Modeling of the Bipolar Disorder and Schizophrenia Using Patient-Derived Induced Pluripotent Stem Cells with Copy Number Variations of <i>PCDH1</i>5 and <i>RELN</i>. | Ishii T et al. | β | 2019 | β |
| Induced pluripotent stem cells for neural drug discovery. | Farkhondeh A et al. | β | 2019 | β |
| iPSCs-Based Neural 3D Systems: A Multidimensional Approach for Disease Modeling and Drug Discovery. | Costamagna G et al. | β | 2019 | β |
| Modeling Psychiatric Diseases with Induced Pluripotent Stem Cells. | van Hugte E et al. | β | 2019 | β |
| Neuronal migration in the CNS during development and disease: insights from <i>in vivo</i> and <i>in vitro</i> models. | Buchsbaum IY et al. | β | 2019 | β |
| Recent advances of induced pluripotent stem cells application in neurodegenerative diseases. | Amin N et al. | β | 2019 | β |
| Serotonin-induced hyperactivity in SSRI-resistant major depressive disorder patient-derived neurons. | Vadodaria KC et al. | β | 2019 | β |
| Studying Human Neurological Disorders Using Induced Pluripotent Stem Cells: From 2D Monolayer to 3D Organoid and Blood Brain Barrier Models. | Logan S et al. | β | 2019 | β |
| Synapse formation: from cellular and molecular mechanisms to neurodevelopmental and neurodegenerative disorders. | Batool S et al. | β | 2019 | β |
| The Glycogen Synthase Kinase-3 in the Regulation of Ion Channels and Cellular Carriers. | Sopjani M et al. | β | 2019 | β |
| Transcriptome Changes in Relation to Manic Episode. | Lee YC et al. | β | 2019 | β |
| Using human stem cells as a model system to understand the neural mechanisms of alcohol use disorders: Current status and outlook. | Scarnati MS et al. | β | 2019 | β |
| Wnt/Ξ²-catenin signaling in brain development and mental disorders: keeping TCF7L2 in mind. | Bem J et al. | β | 2019 | β |
| An Investigation of <i>SDF1/CXCR4</i> Gene Polymorphisms in Autism Spectrum Disorder: A Family-Based Study. | Kara T et al. | β | 2018 | β |
| Characterization and transplantation of enteric neural crest cells from human induced pluripotent stem cells. | Li W et al. | β | 2018 | β |
| From the Psychiatrist's Couch to Induced Pluripotent Stem Cells: Bipolar Disease in a Dish. | Hoffmann A et al. | β | 2018 | β |
| Induced pluripotent stem cells (iPSCs) as model to study inherited defects of neurotransmission in inborn errors of metabolism. | Jung-Klawitter S et al. | β | 2018 | β |
| Investigating pediatric disorders with induced pluripotent stem cells. | Durbin MD et al. | β | 2018 | β |
| Neural Stem Cell Dysfunction in Human Brain Disorders. | Liszewska E et al. | β | 2018 | β |
| Pathophysiology in the comorbidity of Bipolar Disorder and Alzheimer's Disease: pharmacological and stem cell approaches. | CorrΓͺa-Velloso JC et al. | β | 2018 | β |
| Studying the Brain in a Dish: 3D Cell Culture Models of Human Brain Development and Disease. | Brown J et al. | β | 2018 | β |
| THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. | Guennewig B et al. | β | 2018 | β |
| The research domain criteria framework in drug discovery for neuropsychiatric diseases: focus on negative valence. | Nicholson JR et al. | β | 2018 | β |
| An update on stem cell biology and engineering for brain development. | Parr CJC et al. | β | 2017 | β |
| Application of induced pluripotent stem cells to understand neurobiological basis of bipolar disorder and schizophrenia. | Liu YN et al. | β | 2017 | β |
| Are reprogrammed cells a useful tool for studying dopamine dysfunction in psychotic disorders? A review of the current evidence. | Sauerzopf U et al. | β | 2017 | β |
| Brain imaging genetics in ADHD and beyond - Mapping pathways from gene to disorder at different levels of complexity. | Klein M et al. | β | 2017 | β |
| Diagnostic and therapeutic potential of microRNAs in neuropsychiatric disorders: Past, present, and future. | Alural B et al. | β | 2017 | β |
| Expression of HDAC2 but Not HDAC1 Transcript Is Reduced in Dorsolateral Prefrontal Cortex of Patients with Schizophrenia. | Schroeder FA et al. | β | 2017 | β |
| Human induced pluripotent stem cells for modelling neurodevelopmental disorders. | Ardhanareeswaran K et al. | β | 2017 | β |
| Modeling neurodevelopmental and psychiatric diseases with human iPSCs. | Wen Z | β | 2017 | β |
| Molecular genetics and targeted therapy of WNT-related human diseases (Review). | Katoh M et al. | β | 2017 | β |
| Molecular Mechanisms of Bipolar Disorder: Progress Made and Future Challenges. | Kim Y et al. | β | 2017 | β |
| Olfactory Neuroepithelial Neural Progenitor Cells from Subjects with Bipolar I Disorder. | Gao Y et al. | β | 2017 | β |
| Personalized medicine in a dish: the growing possibility of neuropsychiatric disease drug discovery tailored to patient genetic variants using stem cells. | Brennand KJ | β | 2017 | β |
| Pluripotent stem cells in neuropsychiatric disorders. | Soliman MA et al. | β | 2017 | β |
| Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesis. | Tobe BTD et al. | β | 2017 | β |
| Stem cell-derived neurons in the development of targeted treatment for schizophrenia and bipolar disorder. | Watmuff B et al. | β | 2017 | β |
| Systematic assessment of environmental risk factors for bipolar disorder: an umbrella review of systematic reviews and meta-analyses. | Bortolato B et al. | β | 2017 | β |
| The use of brain organoids to investigate neural development and disease. | Di Lullo E et al. | β | 2017 | β |
| Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions. | Tomasetti C et al. | β | 2017 | β |
| Unraveling the biology of bipolar disorder using induced pluripotent stem-derived neurons. | Miller ND et al. | β | 2017 | β |
| Wnt and GSK3 Signaling Pathways in Bipolar Disorder: Clinical and Therapeutic Implications. | Muneer A | β | 2017 | β |
| Accumulating evidence for a role of TCF7L2 variants in bipolar disorder with elevated body mass index. | Cuellar-Barboza AB et al. | β | 2016 | β |
| A Dishful of a Troubled Mind: Induced Pluripotent Stem Cells in Psychiatric Research. | KΓ‘lmΓ‘n S et al. | β | 2016 | β |
| Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models. | Haggarty SJ et al. | β | 2016 | β |
| Chemokine and Chemokine Receptor Polymorphisms in Bipolar Disorder. | Tokac D et al. | β | 2016 | β |
| Concise Review: Progress and Challenges in Using Human Stem Cells for Biological and Therapeutics Discovery: Neuropsychiatric Disorders. | Panchision DM | β | 2016 | β |
| Decoding the non-coding genome: elucidating genetic risk outside the coding genome. | Barr CL et al. | β | 2016 | β |
| Disease signatures for schizophrenia and bipolar disorder using patient-derived induced pluripotent stem cells. | Watmuff B et al. | β | 2016 | β |
| Forced cell cycle exit and modulation of GABAA, CREB, and GSK3Ξ² signaling promote functional maturation of induced pluripotent stem cell-derived neurons. | Telezhkin V et al. | β | 2016 | β |
| Genetics of Bipolar Disorder: Recent Update and Future Directions. | Goes FS | β | 2016 | β |
| Human iPSC-derived neurons and lymphoblastoid cells for personalized medicine research in neuropsychiatric disorders. | Gurwitz D | β | 2016 | β |
| Innovative approaches to bipolar disorder and its treatment. | Harrison PJ et al. | β | 2016 | β |
| Inositol depletion, GSK3 inhibition and bipolar disorder. | Yu W et al. | β | 2016 | β |
| Modeling developmental neuropsychiatric disorders with iPSC technology: challenges and opportunities. | Young-Pearse TL et al. | β | 2016 | β |
| Modeling psychiatric disorders with patient-derived iPSCs. | Wen Z et al. | β | 2016 | β |
| Molecular neurobiological clues to the pathogenesis of bipolar disorder. | Harrison PJ | β | 2016 | β |
| Neurodevelopmental origins of bipolar disorder: iPSC models. | O'Shea KS et al. | β | 2016 | β |
| Pluripotent stem cells in disease modelling and drug discovery. | Avior Y et al. | β | 2016 | β |
| Reduced CYFIP1 in Human Neural Progenitors Results in Dysregulation of Schizophrenia and Epilepsy Gene Networks. | Nebel RA et al. | β | 2016 | β |
| Serotonergic neurons derived from induced pluripotent stem cells (iPSCs): a new pathway for research on the biology and pharmacology of major depression. | Licinio J et al. | β | 2016 | β |
| The effect of lithium on hematopoietic, mesenchymal and neural stem cells. | Ferensztajn-Rochowiak E et al. | β | 2016 | β |
| The promises and challenges of human brain organoids as models of neuropsychiatric disease. | Quadrato G et al. | β | 2016 | β |
| Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding. | Malhi GS et al. | β | 2016 | β |
| Update on bipolar disorder biomarker candidates. | Teixeira AL et al. | β | 2016 | β |
| Using Induced Pluripotent Stem Cells to Investigate Complex Genetic Psychiatric Disorders. | Temme SJ et al. | β | 2016 | β |
| RNA Sequencing in Schizophrenia. | Li X et al. | β | 2015 | β |
| Transcriptomic Analysis of Induced Pluripotent Stem Cells Derived from Patients with Bipolar Disorder from an Old Order Amish Pedigree. | Kim KH et al. | β | 2015 | β |